131 related articles for article (PubMed ID: 2783335)
21. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
[TBL] [Abstract][Full Text] [Related]
22. Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma.
Asaoku H; Kawano M; Iwato K; Tanabe O; Tanaka H; Hirano T; Kishimoto T; Kuramoto A
Blood; 1988 Aug; 72(2):429-32. PubMed ID: 3261180
[TBL] [Abstract][Full Text] [Related]
23. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation.
Borset M; Helseth E; Naume B; Waage A
Br J Haematol; 1993 Nov; 85(3):446-51. PubMed ID: 8136264
[TBL] [Abstract][Full Text] [Related]
24. Establishment of a human myeloma cell line with growth-promoting activity for bone marrow-derived fibroblastoid colony-forming cells.
Takahira H; Kozuru M; Hirata J; Obama K; Uike N; Iguchi H; Miyamura T; Yamashita S; Kono A; Umemura T
Exp Hematol; 1994 Mar; 22(3):261-6. PubMed ID: 8112425
[TBL] [Abstract][Full Text] [Related]
25. C-kit ligand (SCF) in human multiple myeloma cells.
Lemoli RM; Fortuna A
Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
[TBL] [Abstract][Full Text] [Related]
26. [The interaction of vascular endothelial growth factor and interleukin-6 in multiple myeloma].
Zhang L; Chen SL; Chen WM; Liu JW
Zhonghua Nei Ke Za Zhi; 2005 Feb; 44(2):85-8. PubMed ID: 15840215
[TBL] [Abstract][Full Text] [Related]
27. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.
Thomas X; Anglaret B; Magaud JP; Epstein J; Archimbaud E
Leuk Lymphoma; 1998 Dec; 32(1-2):107-19. PubMed ID: 10037006
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M
Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.
Jernberg H; Pettersson M; Kishimoto T; Nilsson K
Leukemia; 1991 Mar; 5(3):255-65. PubMed ID: 1707469
[TBL] [Abstract][Full Text] [Related]
31. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
32. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
33. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.
Zhang XG; Gu JJ; Lu ZY; Yasukawa K; Yancopoulos GD; Turner K; Shoyab M; Taga T; Kishimoto T; Bataille R
J Exp Med; 1994 Apr; 179(4):1337-42. PubMed ID: 8145045
[TBL] [Abstract][Full Text] [Related]
34. Response patterns of purified myeloma cells to hematopoietic growth factors.
Anderson KC; Jones RM; Morimoto C; Leavitt P; Barut BA
Blood; 1989 May; 73(7):1915-24. PubMed ID: 2713508
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 1 autocrine growth system in human multiple myeloma.
Nagata K; Tanaka Y; Oda S; Yamashita U; Eto S
Jpn J Clin Oncol; 1991 Feb; 21(1):22-9. PubMed ID: 2067118
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
Kovacs E
Leuk Res; 2010 Jul; 34(7):912-6. PubMed ID: 19762082
[TBL] [Abstract][Full Text] [Related]
37. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
38. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
[TBL] [Abstract][Full Text] [Related]
39. Cytokine network in human multiple myeloma.
Klein B; Bataille R
Hematol Oncol Clin North Am; 1992 Apr; 6(2):273-84. PubMed ID: 1582974
[TBL] [Abstract][Full Text] [Related]
40. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
